Stockscreener 앱 받기
87.00
29.77%
19.96
시간 외 거래:
87.38
0.38
+0.44%
전일 마감가:
$67.04
열려 있는:
$67.39
하루 거래량:
7.05M
Relative Volume:
7.97
시가총액:
$5.41B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
33.21
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
+34.20%
1개월 성능:
+50.68%
6개월 성능:
+112.77%
1년 성능:
+99.59%
1일 변동 폭
$65.75
$93.25
1주일 범위
$62.24
$93.25
52주 변동 폭
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
87.00 | 4.17B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs - ts2.tech
Protagonist Therapeutics Inc. (PTGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Protagonist Therapeutics stock reaches all-time high at 73.34 USD - Investing.com
Protagonist Therapeutics Sees Surging Stock Price: What’s Driving This? - StocksToTrade
Why Did Protagonist Therapeutics Stock Soar Today? - MSN
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - Reuters
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Benzinga
Protagonist Therapeutics (PTGX) Stock Surges Over 34% - GuruFocus
Stocks making the biggest moves midday: MP Materials, Alibaba, Protagonist Therapeutics & more - CNBC
Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ - Bloomberg.com
Protagonist Therapeutics (PTGX) Surges on Potential Johnson & Jo - GuruFocus
Protagonist Therapeutics surges after media reports J&J in talks to buy co - TradingView
J&J reportedly in talks to buy Protagonist (JNJ:NYSE) - Seeking Alpha
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports - Yahoo Finance
Protagonist Therapeutics stock surges after J&J acquisition talks report By Investing.com - Investing.com South Africa
Johnson & Johnson In Talks To Buy Protagonist TherapeuticsWSJ - TradingView
Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics - The Wall Street Journal
Protagonist Therapeutics' (PTGX) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
What machine learning models say about Protagonist Therapeutics Inc.July 2025 Decliners & Weekly High Potential Stock Alerts - newser.com
Protagonist Stock Surges on Johnson & Johnson Report - The Wall Street Journal
Using data models to predict Protagonist Therapeutics Inc. stock movementPortfolio Risk Report & Weekly Watchlist of Top Performers - newser.com
Is Protagonist Therapeutics Inc. a candidate for recovery play2025 Top Decliners & Technical Confirmation Trade Alerts - newser.com
Predicting Protagonist Therapeutics Inc. trend using moving averages2025 Short Interest & Stepwise Entry/Exit Trade Alerts - newser.com
Protagonist Therapeutics (PTGX): Evaluating Valuation After Positive Phase 2b Trial Data and Pipeline Momentum - simplywall.st
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Livingston Daily
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - DelmarvaNow.com
Protagonist Therapeutics Inc Stock Analysis and ForecastMorning Star Patterns & Get Alerts on Stocks Set to Skyrocket - earlytimes.in
BMO Capital reiterates Outperform rating on Protagonist Therapeutics stock By Investing.com - Investing.com Canada
Protagonist Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Will Icotrokinra’s Phase 2b Success Shift Protagonist Therapeutics' (PTGX) Ulcerative Colitis Narrative? - simplywall.st
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - USA Today
Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target Price | PTGX Stock News - GuruFocus
Protagonist Therapeutics stock price target raised to $74 at Clear Street - Investing.com
Protagonist Therapeutics (PTGX) Reports Promising Phase 2b Resul - GuruFocus
Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge - Yahoo Finance
Why Protagonist Therapeutics Inc. stock could be next big winnerWeekly Stock Report & Daily Profit Maximizing Tips - newser.com
How to escape a deep drawdown in Protagonist Therapeutics Inc.July 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
Can Protagonist Therapeutics Inc. stock hit record highs againMarket Rally & Free Safe Capital Growth Stock Tips - newser.com
Short interest data insights for Protagonist Therapeutics Inc.Day Trade & Expert Approved Trade Ideas - newser.com
Sentiment analysis tools applied to Protagonist Therapeutics Inc.Quarterly Profit Summary & Safe Investment Capital Preservation Plans - newser.com
Protagonist Therapeutics, Inc. $PTGX Shares Bought by State of Alaska Department of Revenue - MarketBeat
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Protagonist Therapeutics Inc 주식 (PTGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Sep 22 '25 |
Sale |
64.25 |
4,000 |
257,000 |
5,130 |
5.74%
자본화:
|
볼륨(24시간):